Cancer Clinical Trials

The New Mexico Heart Institute (NMHI), a department of Lovelace Medical Center, is a leader in the nation when it comes to research and clinical trials as it relates to cardiac care. Our cardiology team is committed to finding treatments for a variety of cardiac conditions. Clinical Research also plays a vital role in the development of products to combat diseases, treat chronic and degenerative diseases and improve the health of people around the world.

Our mission

The Clinical Research Department at Lovelace Medical Center is an innovative team dedicated to engaging in pioneered science for global healthcare solutions to enhance the health of communities we serve. Clinical research is important because it can show researchers what does and doesn’t work. Some studies are designed for, or include, people who are healthy but want to help find ways to prevent a disease, such as one that may be common in their family. Volunteers who take part in clinical trials make valuable contributions to advancing the understanding of diseases and the discovery of new or improved treatments.

What to expect

• Consent – Before participating, your health care professional or research study coordinator will share the details about the study. They will explain things like the purpose of the study, potential benefits, side effects, treatment plan and duration. If you agree to participate, you will sign an informed consent document. You should not sign this consent unless all your questions have been answered. A copy of the consent will be provided to you.
• Participate – Once you agree to participate, you may have tests and procedures associated with the clinical trial guidelines. The study coordinator is responsible for ensuring all guidelines are followed and to help keep participants safe. Your participation is voluntary, and you may change your mind at any time during the clinical trial.
• Qualify – Clinical trial participants must meet certain criteria like age, type of disease, previous treatments, and other medical conditions. Your healthcare professional will help determine if you are a candidate for the trial.

Our team of skilled experts work directly with our patients to help educate about the trial, gather necessary data, treat the patients accordingly, and help manage our patients care.

Breast

Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03	Alliance Foundation	PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)- negative Early Breast Cancer
NSABP B-55/BIG 6-13	NSABP	NSABP B-55/BIG 6-13: A Randomized, Double-Blind, Parallel Group, Placebo- Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
SWOG S1207	SWOG	Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Alliance A011502	Alliance	A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131	ECOG-ACRIN	A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple- Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1418/BR006	NSABP	A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
SWOG S1416	SWOG	SWOG S1416: Phase II Randomized Placebo- Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple- Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
NRG-BR002	NRG	A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Alliance Foundation Trials AFT-38	Alliance Foundation	A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2- Positive Metastatic Breast Cancer
Pharm CP-MGAH22-04	MacroGenics, Inc.	A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A011401	Alliance	Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Alliance A011202	Alliance	Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A011401	Alliance	Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
INST CR1701	Institutional	Assessment of Intraoperative Radiofrequency Spectroscopy For Improving Lumpectomy Outcomes with Respect to Re-excision Rates and Lumpectomy Size
NSABP B-51	NRGO	A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B- 51/RTOG-1304)
NRG-BR002	NRG	A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

Cervical

GOG 0263	NRG	Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
RTOG 0724/GOG-0724	NRG	Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Gastrointestinal

Alliance A021502	Alliance	Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG S1613	SWOG	A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
SWOG S0820	SWOG	A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
SWOG S1505	SWOG	A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification

Hematology

SWOG S1612

SWOG

A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older (LEAP: Intergroup Less Intense AML Platform Trial)

Lung

ECOG-ACRIN EA5142	ECOG-ACRIN	Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Alliance A081105	Alliance	Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC); AKA ALCHEMIST
Alliance A151216	Alliance	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512	ECOG-ACRIN	A Phase III Double-Blind Trial for Surgically Resected Early St Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG S1403	SWOG	A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Naïve Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer
NRG-LU002	NRG	Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
SWOG S1400	SWOG	Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
SWOG S1400F	SWOG	A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB- STUDY)
SWOG S1400G	SWOG	SWOG S1400G: A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG 1400I	SWOG	A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
NRG Oncology NRG- LU002	NRG	Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

Multiple sites/other

SWOG S1609	SWOG	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
INST 96144	City of Hope	Molecular Genetics Studies of Cancer Patients and Their Relatives
DCP-001	Division of Cancer Prevention	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Prostate

NRG Oncology NRG- GU003	NRG	A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
NRG Oncology NRG- GU003	NRG	Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

Skin/Melanoma

SWOG S1616	SWOG	A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC- 732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD- 1 or Anti-PD-L1 Agent
ECOG-ACRIN EA6134	ECOG-ACRIN	A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma